Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.069 CHF | -8.73% | +4.55% | +68.29% |
May. 01 | SIX Swiss Exchange Approves Delay in Spexis' FY23 Annual Report Publication | MT |
Apr. 17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
Sales 2021 | 331 363.3 | Sales 2022 | 1.48M 1.62M | Capitalization | 19.96M 21.91M |
---|---|---|---|---|---|
Net income 2021 | -11M -12.07M | Net income 2022 | -18M -19.76M | EV / Sales 2021 * | - |
Net cash position 2021 | 6.23M 6.84M | Net Debt 2022 | 4.23M 4.65M | EV / Sales 2022 | 16.4 x |
P/E ratio 2021 * |
-
| P/E ratio 2022 |
-1.07
x | Employees | 28 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 50.23% |
Latest transcript on Spexis AG
1 day | -8.73% | ||
1 week | -11.31% | ||
Current month | +17.35% | ||
1 month | +25.45% | ||
3 months | -65.50% | ||
6 months | +98.28% | ||
Current year | +68.29% |
Managers | Title | Age | Since |
---|---|---|---|
Jeffrey Wager
CEO | Chief Executive Officer | 62 | 21-12-29 |
Martin Jakobovic
DFI | Director of Finance/CFO | - | - |
Stephan Wehselau
COO | Chief Operating Officer | 55 | 21-12-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dan Hartman
BRD | Director/Board Member | 62 | 21-12-29 |
Dennis Ausiello
BRD | Director/Board Member | 78 | 21-12-29 |
Kuno Sommer
BRD | Director/Board Member | 68 | 12-08-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-21 | 0.069 | -8.73% | 38,937 |
24-05-17 | 0.0756 | -2.83% | 66,021 |
24-05-16 | 0.0778 | +12.75% | 78,544 |
24-05-15 | 0.069 | +4.55% | 149,533 |
24-05-14 | 0.066 | -15.17% | 206,976 |
Delayed Quote Swiss Exchange, May 21, 2024 at 11:31 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+68.29% | 5.62M | |
-3.15% | 89.69B | |
+2.50% | 41.34B | |
-12.01% | 33.72B | |
+62.74% | 26.11B | |
-19.79% | 14.63B | |
-8.58% | 12.84B | |
-12.34% | 11.66B | |
-43.92% | 11.52B | |
+4.27% | 8.92B |
- Stock Market
- Equities
- POLN Stock